The risks ‘higher for longer’ rates pose to private equity

The possibility of higher-for-longer US rates may not materially affect the overall economy, but it could challenge private-equity-backed businesses.
Seeking value in the auto sector

Covid-related supply chain disruptions had a dramatic impact on the industry, curtailing demand by around 30m units, or around one-third of pre-pandemic global auto sales.
Finding opportunities amid uncertainty

We are targeting non-US listed multinationals with significant exposure to the US economy as an attractively priced way to exploit any soft landing in America.
Keeping an open mind on interest rates

US inflation is proving stickier than expected. We believe this trend could continue – and with the economy also remaining relatively resilient, investors need to be open-minded to the prospect that rates will remain higher for longer.
Good Value Briefing | Goldilocks: perhaps a fairy-tale, but markets still present opportunities

As the S&P 500 continues to set new records, the market is taking the view that inflation has been tamed and rates can fall while economic growth and employment remain intact.
Finding value among global cyclicals

Investors should tread carefully amid uncertainty over US interest rates.
Unearthing tomorrow’s stock-market winners

Every investor knows that past performance is no guarantee of future results, yet it’s tempting to assume stocks that outperformed last year will do so again in 2024.
Tomorrow’s winners; five mispriced opportunities

Global equities had a strong 2023. Performance for most of the year was driven by the seven largest tech stocks. However, the back end of the year saw an increase in breadth as the 2023 laggards began to rally.
Good Value Briefing | Tomorrow’s winners – five mispriced opportunities

Global equities had a strong 2023. Performance for most of the year was driven by the seven largest tech stocks. However, the back end of the year saw an increase in breadth as the 2023 laggards began to rally.
Medical-device sector well placed to shine in 2024

The media hype around booming demand for glucagon-like peptide 1 (GLP-1) drugs, and their weight-loss abilities, has distracted the attention of healthcare investors from the potential of medical-device companies.